[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sheng Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,79,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100616758","phase-2-trastuzumab-rezetecan-in-advanced-solid-tumors-refractory-to-standard-therapies-100616758",false,"NCT07309770","Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies","Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies: A Multicenter, Single-Arm, Phase II Study With Multiple Cohorts","Inclusion Criteria:\n\nVoluntarily sign a written informed consent form.\n\nAge ≥ 18 years.\n\nDiagnosed with the corresponding advanced tumor confirmed by histology and\u002For cytology, combined with imaging or ultrasound assessment, and pathologically confirmed as HER2-positive (i.e., HER2 ≥ 1+ by immunohistochemistry \\[IHC\\]).\n\nCohort 1 only: Histologically confirmed extramammary Paget's disease (EMPD) with unresectable locally advanced or metastatic disease.\n\nCohort 2 only: Histologically confirmed locally advanced or metastatic rare solid tumor (e.g., sarcoma, urachal cancer) refractory to standard treatment or for whom no standard treatment is available.\n\nCohort 3 only: Histologically confirmed locally advanced or metastatic urothelial carcinoma with disease progression following first-line treatment with a PD-1\u002FPD-L1 inhibitor combined with enfortumab vedotin or disitamab vedotin.\n\nECOG Performance Status: 0 to 2.\n\nAt least one measurable lesion (according to RECIST v1.1 criteria: non-nodal lesions with longest diameter ≥10 mm on CT scan, nodal lesions with short axis ≥15 mm on CT scan).\n\nHematological function:\n\nAbsolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹\u002FL\n\nPlatelet count (PLT) ≥ 70 × 10⁹\u002FL\n\nHemoglobin (HGB) ≥ 80 g\u002FL\n\nHepatic function:\n\nSerum total bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal (ULN)\n\nAlanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if liver metastases are present)\n\nSerum albumin ≥ 28 g\u002FL\n\nRenal function:\n\nSerum creatinine (Cr) ≤ 1.5 × ULN or Creatinine clearance ≥ 50 mL\u002Fmin (calculated using the standard Cockcroft-Gault formula)\n\nCoagulation function:\n\nInternational Normalized Ratio (INR) ≤ 1.5 and\u002For Prothrombin Time (PT) ≤ 1.5 × ULN\n\nActivated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN\n\nEstimated life expectancy ≥ 3 months.\n\nUse of medically approved contraception during the treatment period and for at least 120 days after the end of the study; sperm donation or cryopreservation for fertilization purposes is not allowed during this period.\n\nAbility to comply with the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded from participation in this study:\n\nPresence of any severe and\u002For uncontrolled disease, including:\n\nPoorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); poorly controlled diabetes (fasting blood glucose \\[FBG\\] \\> 10 mmol\u002FL).\n\n≥ Grade 2 myocardial ischemia, myocardial infarction, arrhythmia (QTcF ≥ 470 ms), or ≥ Grade 2 congestive heart failure (New York Heart Association \\[NYHA\\] classification).\n\nActive or uncontrolled severe infection (≥ CTCAE Grade 2 infection) requiring systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis infection.\n\nHistory of active tuberculosis.\n\nUncontrolled ascites, pericardial effusion, or pleural effusion requiring repeated drainage.\n\nActive hepatitis (liver enzyme levels not meeting inclusion criteria; for Hepatitis B: HBV DNA ≥ 2000 IU\u002Fml or ≥ 10⁴ copies\u002Fml; for Hepatitis C: HCV RNA ≥ 2000 IU\u002Fml or ≥ 10⁴ copies\u002Fml; carriers with chronic hepatitis B virus \\[HBV DNA \\\u003C 10⁴ IU\u002Fml\\] may be enrolled if they receive concomitant antiviral therapy during the trial).\n\nHistory of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases.\n\nKnown history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n\nKnown presence of brain metastases, leptomeningeal metastasis, spinal cord compression, or spinal metastasis.\n\nWithin 6 months prior to the first dose: history of esophageal\u002Fgastric varices, severe ulcer, unhealed wound, gastrointestinal perforation, abdominal fistula, intestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding; extensive intestinal resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.\n\nPresence of non-healing or poorly healed wounds, active ulcers.\n\nToxicity from previous antineoplastic therapy that has not resolved to ≤ Grade 1 per NCI CTCAE v5.0 (except for alopecia).\n\nMajor surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to the start of study treatment; or presence of long-term unhealed wounds or fractures.\n\nHistory of severe hypersensitivity reaction to monoclonal antibodies; known allergy to the active components or excipients of the study drug(s).\n\nParticipation in another clinical trial within 4 weeks prior to the start of the study.\n\nAdministration of a live vaccine within 30 days prior to the first dose, or planned administration during the study.\n\nHistory of severe allergy.\n\nBleeding tendency, coagulopathy, or undergoing thrombolytic therapy.\n\nHistory of drug abuse or inability to discontinue use, or history of psychiatric disorders.\n\nHistory of clear neurological or psychiatric disorders, such as dementia, epilepsy, or susceptibility to seizures.\n\nAny condition that, in the investigator's judgment, seriously endangers subject safety, affects subject completion of the study (e.g., severe diabetes, thyroid disease, psychosis), may compromise subject safety or the ability to provide informed consent (including abnormal laboratory findings), or involves psychological, familial, sociological, or geographical conditions that may preclude compliance with the study protocol and follow-up plan.\n\nAny other reason deemed by the investigator to make the subject unsuitable for participation in this clinical trial.","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent. A total of 90 patients were allocated into three cohorts (30 patients each): those with Extramammary Paget's Disease (EMPD), rare solid tumors, or urothelial carcinoma, who had experienced failure of standard treatment or for whom no standard treatment was available. The participant recruitment period was 12 months, and the follow-up duration was 12 months. All patients received Trastuzumab Rezetecan (SHR-A1811) at a dose of 4.8 mg\u002Fkg administered every three weeks (q3w). They were followed until disease progression, withdrawal from the study, loss to follow-up, or death, whichever occurred first. Tumor response was assessed radiologically every 6 weeks during treatment. Safety follow-up was conducted 30 days after the last dose, followed by survival follow-up every 3 months thereafter.",[26,27,28],"Urachal Cancer","Advanced Solid Tumor Cancer","Antibody-drug Conjugates",[30,31,32,33,34],"Antibody-Drug Conjugates","Rare tumor","Extra-mammary Paget disease","Urachal cancer","Trastuzumab Rezetecan","RECRUITING","2025-12-15",{"date":38,"type":39},"2025-12-30","ACTUAL",{"date":41,"type":20},"2025-12-18",{"date":43,"type":20},"2028-03-11",{"name":45,"class":46},"Sheng Zhang","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100605625","compression-stockings-to-prevent-peripheral-neuropathy-caused-by-antibody-drug-conjugates-in-urothelial-carcinoma-patients-100605625","NCT07164950","Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients","A Multicenter, Prospective, Phase II Clinical Trial Investigating the Use of Compression Stockings to Prevent Peripheral Neuropathy Induced by Antibody-Drug Conjugates (ADCs) in Patients With Urothelial Carcinoma","Inclusion Criteria:\n\n* Age ≥ 18 years Histologically or cytologically confirmed advanced malignancy (including but not limited to urothelial carcinoma) eligible for MMAE-containing ADC therapy (e.g., EV, DV, BV)\n* ECOG performance status 0-2\n* No baseline peripheral neuropathy ≥ Grade 1 (CTCAE v5.0)\n* Stable tumor status without other neurotoxic drugs in the past 2 months\n* Adequate organ function (blood counts, liver and kidney function) per protocol\n* Expected survival ≥ 3 months\n* Ability and willingness to comply with study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Poor compliance or inability to follow protocol\n* Pre-existing peripheral neuropathy ≥ Grade 1 from prior platinum\u002Ftaxane treatment\n* Severe diabetes or peripheral vascular disease\n* Neurological disorders causing nerve compression (e.g., carpal tunnel syndrome, radiculopathy)\n* Severe psychiatric conditions (depression, bipolar disorder, substance abuse)\n* Active uncontrolled infections requiring systemic antibiotics\u002Fantifungals\u002Fantivirals (≥ CTCAE Grade 2)\n* Active hepatitis or significant liver dysfunction not meeting inclusion criteria\n* Renal failure requiring dialysis\n* Immunodeficiency or history of organ transplantation\n* Severe nausea, headache, fatigue, or other debilitating symptoms\n* Active tuberculosis or uncontrolled pleural\u002Fpericardial effusion\u002Fascites\n* Hypersensitivity to monoclonal antibodies or study device components\n* Participation in other clinical trials within 4 weeks\n* Known bleeding or coagulation disorders or receiving thrombolytic therapy\n* Any other condition judged by the investigator to preclude safe participation","75 Years",{"count":57,"type":20},58,[59],"NA","This multicenter, prospective phase II clinical trial aims to evaluate the efficacy and safety of medical compression stockings in preventing peripheral neuropathy induced by antibody-drug conjugates (ADCs) containing monomethyl auristatin E (MMAE) in patients with advanced cancers, including urothelial carcinoma. Eligible participants will have no baseline ≥ grade 1 neuropathy and will be scheduled to receive MMAE-containing ADC therapy. A total of 58 patients will be enrolled and followed for 24 months. In this self-controlled design, the left foot will be fitted with a medical compression stocking while the right foot remains uncovered, starting 15 minutes before infusion and continuing until 15 minutes after infusion (total duration: 120 minutes). Peripheral neuropathy will be assessed before treatment, after cycle 3, within 1 week after treatment completion, and 1 month after completion, using CTCAE v5.0 and patient-reported questionnaires (QLQ-C30 and FACT-GOG-NTx). Toe temperature will be measured to assess local microcirculation changes. The study will also monitor compression-related adverse events. The results will provide evidence for preventive strategies to reduce ADC-induced peripheral neuropathy and improve patients' quality of life.",[62,63,64,28],"Urothelial Carcinoma","Advanced Solid Tumors","Chemotherapy-Induced Peripheral Neuropathy",[30,66,67,68,69,70],"Peripheral Neuropathy Prevention","Compression Stockings","Advanced Cancer","Quality of Life","Mechanical Compression Therapy","2025-09-11",{"date":73,"type":39},"2025-09-15",{"date":75,"type":39},"2025-08-30",{"date":77,"type":20},"2026-07-01",{"name":45,"class":46},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100600308","phase-2-ivonescimab-pd-1vegf-bispecific-antibody-plus-radiofrequency-ablation-for-multiple-advanced-tumors-after-pd-1-therapy-failure-100600308","NCT07095803","Ivonescimab (PD-1\u002FVEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure","Ivonescimab (PD-1\u002FVEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure: A Multicohort, Multicenter, Single-Arm Phase II Study","Inclusion Criteria:\n\n* Voluntarily provide written informed consent\n* Age ≥18 years old\n* Histologically and\u002For cytologically confirmed advanced tumors as assessed by imaging or ultrasound\n* ECOG score: 0-2\n* At least one measurable lesion (according to RECIST criteria, the major diameter of non-lymph node lesions on CT scan ≥10 mm, and the minor diameter of lymph node lesions on CT scan ≥15 mm); There are other lesions that can be treated with radiofrequency\n* Blood routine: Absolute Neutrophil Count (ANC) 1.5×10\\^9\u002FL, Platelet (PLT) ≥70×10\\^9\u002FL, Hemoglobin (HGB) ≥80g\u002FL\n* Liver function: serum Total Bilirubin (TBIL) ≤1.5× Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Transferase (AST) ≤3×ULN, and AST and ALT ≤5.0 ULN in patients with liver metastasis; Serum albumin ≥28 g\u002FL\n* Renal function: serum Creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥50 mL\u002Fmi (using the standard Cockcroft-Gault formula) 9. Coagulation: International Normalized Ratio (INR) ≤1.5 \u002FPT≤1.5×ULN, aPTT≤1.5×ULN\n* Estimated survival time ≥3 months\n* Use of a medically approved contraceptive method is required during the study treatment period and for at least 120 days after the end of the study, and sperm donation or cryopreservation for fertilization and reproduction is not permitted during this period\n* Ability to adhere to study access schedules and other protocol requirements\n\nExclusion Criteria:\n\n* Subjects with any severe and\u002For uncontrolled illness. These include:\n\n  1. poor blood pressure control (systolic blood pressure ≥150 MMHG or diastolic blood pressure ≥100 MMHG); Poorly controlled diabetes (fasting blood glucose \\[FBG\\] \\> 10mmol\u002FL);\n  2. with ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (QTc≥470ms), and ≥ grade 2 congestive heart failure (New York Heart Association \\[NYHA\\] classification); And 3) severe active or uncontrolled infections (≥CTCAE grade 2 infection) requiring systemic antibacterial, antifungal, or antiviral therapy, including pulmonary tuberculosis infection.\n\n  4\\) patients with a history of active tuberculosis; 5) If it is not controlled, ascites, pericardial effusion and pleural effusion still need repeated drainage\n* Active hepatitis (transaminase did not meet the inclusion criteria, hepatitis B reference: HBV DNA≥2000 IU\u002Fml or ≥104 copies \u002Fml; Hepatitis C reference: HCV RNA≥2000 IU\u002Fml or ≥104 copies \u002Fml; After nucleotide antiviral therapy, those below the above criteria can be enrolled). Chronic hepatitis B virus carriers with HBV DNA \\\u003C 104 IU\u002Fml could only be enrolled if they received antiviral therapy at the same time during the trial\n* A history of immunodeficiency, including HIV infection or other acquired or congenital immunodeficiency diseases\n* Active autoimmune disease requiring systemic treatment within 2 years before the initiation of treatment, or autoimmune disease with potential recurrence or planned treatment as judged by the investigator; Exceptions include skin diseases that do not require systemic treatment (e.g., vitiligo, alopecia, psoriasis, or eczema); Hypothyroidism due to autoimmune thyroiditis requires only stable doses of hormone replacement therapy. Well-controlled type I diabetes; Subjects who have had complete remission of childhood asthma without any intervention in adulthood; The investigator judged that the disease would not recur in the absence of an external trigger\n* Received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc., excluding IL-11 for thrombocytopenia) within 2 weeks before the first dose\n* Subjects required systemic treatment with corticosteroids (\\>10mg prednisone equivalent per day) or other immunosuppressive drugs within 14 days prior to study initiation. Subjects allowed topical, ocular, intra-articular, intranasal, and inhaled corticosteroids. Physiological alternative doses of systemic corticosteroids are allowed. Allowing short-term use of corticosteroids for prevention (e.g., contrast allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity from contact allergens)\n* Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n* Known presence, leptomeningeal metastasis, spinal cord metastasis or compression\n* History of abdominal fistula or gastrointestinal perforation related to anti-VEGF therapy; Esophagogastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding, extensive bowel resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or long-term chronic diarrhea within 6 months before the first administration of the drug\n* Unhealed or poorly healed wounds or active ulcers\n* Failure to resolve toxicity from previous antineoplastic therapy, defined as failure to return to NCI CTCAE version 5.0 grade 0 or 1\n* Patients who underwent major surgical treatment, open biopsy, or significant traumatic injury within 28 days before the start of study treatment; Or have a wound or fracture that has not healed for a long time\n* Severe hypersensitivity reaction after using monoclonal antibody; Those who were known to be allergic to the active ingredients or excipients of the study\n* Are participating or have participated in other clinical investigators within 4 weeks before study initiation\n* Have received a live vaccine within 30 days before the first dose, or plan to receive a live vaccine during the study\n* Patients with a history of severe allergy\n* At risk of bleeding, or coagulopathy, or receiving thrombolytic therapy\n* Persons with a history of psychotropic drug abuse and inability to quit or mental disorders\n* Subjects who, in the investigator's judgment, had a concomitant medical condition that seriously jeopardized the safety of the subjects or interfered with the completion of the study, or who were deemed to be ineligible for enrollment for any other reason. A clear history of a previous neurological and mental disorder, such as dementia, epilepsy, or seizure prone\n* The presence of concomitant diseases (such as severe diabetes mellitus, thyroid disease, and psychosis), or serious and\u002For unstable medical, psychiatric, or other conditions (including laboratory abnormalities) that, in the judgment of the investigators, seriously compromise the safety of the subjects or prevent the subjects from completing the study, or the presence of serious and\u002For unstable medical, psychiatric, or other conditions (including laboratory abnormalities) that affect the safety of the patients or affect the informed consent of the patients; Or the presence of any psychological, family, sociological or geographical factors that affect the study protocol and follow-up plan\n* The investigator decided that he was not suitable to participate in the trial for any reason",{"count":87,"type":20},60,[23],"The goal of this clinical trial is to learn if the combination of radiofrequency ablation (RFA) and Ivonescimab (PD-1\u002FVEGF Bispecific Antibody) works to could reverse PD-1\u002FPD-L1 resistance in patients with advanced tumors. It will also learn about the safety of this combination. The main questions it aims to answer are:\n\nDoes the combination of RFA and Ivonescimab increase the objective response rate (ORR) of participants? What medical problems do participants have when taking the combination? Will the combination influence the progression-free survival time (PFS) and overall survival time and quality of life (QoL) of participants?\n\nParticipants will:\n\nPatients received RGA treatment for less than three lesions. Patients were treated with Ivonescimab (20mg\u002Fkg Q3W, every 3 weeks) within 1 week before and after radiofrequency treatment until disease progression or intolerable toxicity occurred, or Ivonescimab was used for 2 years. Treatment effects will be evaluated every 9 weeks for 1 year and every 12 weeks thereafter.",[91],"Multiple Advanced Tumors After PD-1 Therapy Failure",[93,94,95,96],"Radiofrequency Ablation","Ivonescimab","Immunotherapy","Advanced Tumors","NOT_YET_RECRUITING","2025-07-23",{"date":100,"type":39},"2025-07-31",{"date":102,"type":20},"2025-08-01",{"date":104,"type":20},"2027-02-01",{"name":45,"class":46},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100596529","phase-2-multi-cohort-single-arm-phase-ii-study-of-the-efficacy-and-side-effects-of-cisplatin-plus-gemcitabine-in-the-treatment-of-pd1-failure-or-intensive-treatment-of-some-rare-tumors-100596529","NCT07046650","Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors","Inclusion Criteria:\n\n* 1\\. Written informed consent was obtained before enrollment. 2. Age ≥18 years old; 3. Patients with corresponding cancer confirmed by histological and\u002For cytological examination; 4. Consent to treatment; 5. ECOG score: 0-1; 6. Previous PD-1 therapy failure; 7. At least one measurable lesion (≥10 mm on CT scan for non-nodal lesions and ≥15 mm on CT scan for nodal lesions according to RECIST criteria).\n\n  8\\. Have adequate organ function: 9. Blood routine: Absolute Neutrophil Count (ANC) 1.5×109\u002FL, Platelet (PLT) ≥70×109\u002FL, Hemoglobin (HGB) ≥80g\u002FL; 10. Liver function: serum Total Bilirubin (TBIL) ≤1.5× Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤3×ULN; Serum albumin ≥28 g\u002FL; Alkaline Phosphatase (ALP) ≤5×ULN; Patients who met the above criteria after conventional liver-protective therapy and could be stable for at least 1 week could be enrolled after investigator's evaluation.\n\n  11\\. Renal function: creatinine clearance ≥60 mL\u002Fmi (using the standard Cockcroft-Gault formula) : 12. Coagulation: International Normalized Ratio (INR) ≤1.5 \u002FPT≤1.5×ULN, aPTT≤1.5×ULN; If the subject is receiving anticoagulant therapy, as long as the PT and INR are within the prescribed range of anticoagulant drugs 13. Estimated survival time ≥3 months; 14. Contraception during treatment 15. Ability to adhere to study access schedules and other protocol requirements.\n\nExclusion Criteria:\n\n* 1\\. Poor patient compliance; 2. Prior exposure to cisplatin and\u002For gemcitabine and documented progression 3. With ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (QTc≥470ms), and ≥ grade 2 congestive heart failure (New York Heart Association \\[NYHA\\] classification); 4. Severe active or uncontrolled infection (≥CTCAE grade 2 infection) requiring systemic antibacterial, antifungal, or antiviral therapy, including pulmonary tuberculosis infection.\n\n  5\\. Active hepatitis (transaminase did not meet the inclusion criteria, hepatitis B reference: HBV DNA≥2000 IU\u002Fml or ≥104 copies \u002Fml; Hepatitis C reference: HCV RNA≥2000 IU\u002Fml or ≥104 copies \u002Fml; After nucleotide antiviral therapy, those below the above criteria can be enrolled). Chronic hepatitis B virus carriers with HBV DNA \\\u003C 104 IU\u002Fml could only be enrolled if they received antiviral therapy at the same time during the trial.\n\n  6\\. A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 7. Severe nausea, headache, insomnia, fatigue, somnolence, dry mouth, dizziness and constipation; 8. Patients with a history of active tuberculosis; 9. Patients who underwent major surgical treatment, open biopsy, or significant traumatic injury within 28 days before the initiation of study treatment; Or have a wound or fracture that has not healed for a long time; 10. Currently participating or having participated in another clinical investigator within 4 weeks before study initiation 11. Patients with a history of severe allergies 12. Is at risk for bleeding, or has coagulopathy, or is receiving thrombolytic therapy 13. People who have a history of psychotropic drug abuse and cannot quit or have mental disorders 14. Subjects who, in the investigator's judgment, had a concomitant medical condition that seriously compromised the safety of the subjects or interfered with the completion of the study, or who were deemed to be ineligible for enrollment for any other reason. \"There was a clear previous history of neurological and psychiatric disorders, such as dementia, epilepsy, or seizure prone episodes.\n\n  15\\. The presence of concomitant diseases (such as severe diabetes mellitus, thyroid disease, and psychosis), or serious and\u002For unstable medical, psychiatric, or other conditions (including laboratory abnormalities) that, in the judgment of the investigators, seriously compromise the safety of the subjects or prevent the subjects from completing the study, or the presence of serious and\u002For unstable medical, psychiatric, or other conditions (including laboratory abnormalities) that affect the safety of the patients or prevent the patients from providing informed consent, \"Or the presence of any psychological, family, sociological, or geographic factors that affect the study protocol and follow-up plan.\n\n  16\\. The investigator did not consider it appropriate to participate in the trial for any reason",{"count":113,"type":20},84,[23],"This is a multi-cohort, single-arm, phase II study of the efficacy and side effects of cisplatin plus gemcitabine in the treatment of PD1 failure or intensive treatment of some rare tumors",[63],"2025-06-30",{"date":119,"type":39},"2025-07-01",{"date":121,"type":39},"2025-01-01",{"date":123,"type":20},"2028-07-31",{"name":45,"class":46},""]